Venture Visionary Partners LLC Sells 2,286 Shares of Johnson & Johnson $JNJ

Venture Visionary Partners LLC reduced its stake in Johnson & Johnson (NYSE:JNJ) by 3.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 67,740 shares of the company’s stock after selling 2,286 shares during the period. Venture Visionary Partners LLC’s holdings in Johnson & Johnson were worth $10,347,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Highline Wealth Partners LLC increased its stake in Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after purchasing an additional 86 shares in the last quarter. Stone House Investment Management LLC acquired a new stake in shares of Johnson & Johnson in the 1st quarter worth about $47,000. 1248 Management LLC bought a new position in Johnson & Johnson in the 1st quarter valued at about $48,000. von Borstel & Associates Inc. acquired a new position in Johnson & Johnson during the 1st quarter valued at about $49,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in Johnson & Johnson during the 1st quarter worth approximately $52,000. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Citigroup lifted their target price on Johnson & Johnson from $185.00 to $200.00 and gave the company a “buy” rating in a research report on Thursday, August 21st. Erste Group Bank raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Royal Bank Of Canada increased their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a report on Thursday, July 17th. Bank of America boosted their price target on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a “neutral” rating in a report on Thursday, July 17th. Finally, UBS Group lifted their target price on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a “buy” rating in a research report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $181.40.

Johnson & Johnson Stock Up 2.1%

JNJ opened at $185.40 on Wednesday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $185.99. The company’s 50-day moving average price is $175.11 and its two-hundred day moving average price is $162.34. The stock has a market cap of $446.51 billion, a price-to-earnings ratio of 19.83, a PEG ratio of 2.31 and a beta of 0.40. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion for the quarter, compared to analysts’ expectations of $22.85 billion. During the same quarter in the previous year, the firm posted $2.82 EPS. Johnson & Johnson’s revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. Johnson & Johnson’s dividend payout ratio is presently 55.61%.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.